A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
Phase of Trial: Phase III
Latest Information Update: 07 Oct 2017
At a glance
- Drugs Lanabecestat (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 25 Aug 2017 Planned End Date changed from 1 Jul 2020 to 30 Sep 2020.
- 25 Aug 2017 Planned primary completion date changed from 1 Jan 2020 to 30 Sep 2020.
- 21 Mar 2017 Status changed from not yet recruiting to recruiting.